FDA Approval Insights: Avapritinib in Indolent Systemic Mastocytosis

0 Görünümler· 07/10/23
OncLive® On Air
OncLive® On Air
0 Aboneler
0
İçinde

Dr Gotlib discusses the significance of the FDA approval of avapritinib in indolent systemic mastocytosis, key findings from the PIONEER trial, and the quality of life benefits that avapritinib provides for patients in this population.

Daha fazla göster

 0 Yorumlar sort   Göre sırala


Bir sonraki